Development and validation of circulating CA125 prediction models in postmenopausal women

BACKGROUND: Cancer Antigen 125 (CA125) is currently the best available ovarian cancer screening biomarker. However, CA125 has been limited by low sensitivity and specificity in part due to normal variation between individuals. Personal characteristics that influence CA125 could be used to improve it...

Descripción completa

Detalles Bibliográficos
Autores principales: Sasamoto, Naoko, Babic, Ana, Rosner, Bernard A., Fortner, Renée T., Vitonis, Allison F., Yamamoto, Hidemi, Fichorova, Raina N., Titus, Linda J., Tjønneland, Anne, Hansen, Louise, Kvaskoff, Marina, Fournier, Agnès, Mancini, Francesca Romana, Boeing, Heiner, Trichopoulou, Antonia, Peppa, Eleni, Karakatsani, Anna, Palli, Domenico, Grioni, Sara, Mattiello, Amalia, Tumino, Rosario, Fiano, Valentina, Onland-Moret, N. Charlotte, Weiderpass, Elisabete, Gram, Inger T., Quirós, J. Ramón, Lujan-Barroso, Leila, Sánchez, Maria-Jose, Colorado-Yohar, Sandra, Barricarte, Aurelio, Amiano, Pilar, Idahl, Annika, Lundin, Eva, Sartor, Hanna, Khaw, Kay-Tee, Key, Timothy J., Muller, David, Riboli, Elio, Gunter, Marc, Dossus, Laure, Trabert, Britton, Wentzensen, Nicolas, Kaaks, Rudolf, Cramer, Daniel W., Tworoger, Shelley S., Terry, Kathryn L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6878636/
https://www.ncbi.nlm.nih.gov/pubmed/31771659
http://dx.doi.org/10.1186/s13048-019-0591-4

Ejemplares similares

Ejemplares similares